Chai Discovery
#3 in Snack-KI & ChatbotsChai Discovery · 4× · tolest 12. Aug. 2026
71
Momentum
Chai Discovery is an AI company founded in San Francisco in 2024 that develops generative models for predicting and designing biomolecules—particularly antibodies. It is NOT a classical conversational chatbot, but rather an AI platform for drug and antibody design in pharmaceutical research. The flagship model Chai-1 (September 2024) is Open Source for structure prediction; Chai-2 (2025) enables de novo antibody design through Zero-Shot generation; Chai-3 is the current commercial version, which has been licensed to Eli Lilly, Pfizer, and Novartis, among others. The company is backed by OpenAI, among others, and reached a valuation of $3.8 billion USD in July 2026 following Series C funding.
Momentum-Verloop
14.05.12.08.
Features
| Autonomy Level | Zero-shot generative design: model autonomously generates antibody candidates from target structure/epitope without prior examples |
| Channels | Web platform (chaidiscovery.com), API/early access for pharma partners, open-source repository on GitHub/Hugging Face |
| License | Chai-1: Apache 2.0 license (code and model weights), usable for both commercial and academic purposes |
| Modalities | Multimodal: proteins, small molecules (SMILES), DNA, RNA, glycosylations, antibody-antigen interactions |
| Platform | Web-hosted tool and Python package (chai_lab, pip install) for Linux with GPU (CUDA); accessible via chaidiscovery.com and GitHub |
| Price | Chai-1 free (open source); Chai-2/Chai-3 available only via early-access/enterprise licensing to partner companies, no public price |
| Release Date | Chai-1 released September 9, 2024 |
